Evidence map›Paper›PMID 29713323›Full record

ArticleFrontiers in immunology2018

Implication of Interleukin-12/15/18 and Ruxolitinib in the Phenotype, Proliferation, and Polyfunctionality of Human Cytokine-Preactivated Natural Killer Cells.

Iñigo Terrén, Idoia Mikelez, Irati Odriozola, Andrea Gredilla, Javier González, Ane Orrantia, Joana Vitallé, Olatz Zenarruzabeitia, Francisco Borrego

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Iñigo TerrénImmunopathology Group, BioCruces Health Research Institute, Barakaldo, Spain.
Idoia MikelezImmunopathology Group, BioCruces Health Research Institute, Barakaldo, Spain.
Irati OdriozolaImmunopathology Group, BioCruces Health Research Institute, Barakaldo, Spain.
Andrea GredillaImmunopathology Group, BioCruces Health Research Institute, Barakaldo, Spain.
Javier GonzálezImmunopathology Group, BioCruces Health Research Institute, Barakaldo, Spain.
Ane OrrantiaImmunopathology Group, BioCruces Health Research Institute, Barakaldo, Spain.
Joana VitalléImmunopathology Group, BioCruces Health Research Institute, Barakaldo, Spain.
Olatz ZenarruzabeitiaImmunopathology Group, BioCruces Health Research Institute, Barakaldo, Spain.
Francisco BorregoImmunopathology Group, BioCruces Health Research Institute, Barakaldo, Spain.
BioCruces Health research Institute · ESIkerbasque · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A brief

Indexed as

AdultCell ProliferationCells, CulturedCytokinesHumansInterleukin-12Interleukin-15Interleukin-18Killer Cells, NaturalNitrilesPhenotypeProtein Kinase InhibitorsPyrazolesPyrimidinesCytokinesIL15 protein, humanIL18 protein, humanInterleukin-12Interleukin-15Interleukin-18NitrilesProtein Kinase InhibitorsPyrazolesPyrimidinesruxolitinibcytokine preactivationcytokine productiondegranulationmemory-like natural killer cellsnatural killer cellspolyfunctionalityruxolitinib

Identifiers

PMID29713323
PMCPMC5911648
OpenAlexW2801350336

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.